This marks a significant milestone in the company’s global expansion of its most advanced portable MRI technology, supporting international commercial growth and improving global access to high-quality brain imaging at the point of care.

Following CE mark and UKCA approval, the next-generation Swoop® system, also known as Model 2, is now commercially available across an initial wave of European markets.